ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meeting Abstracts
    • All Meetings
    • PRSYM 2026
    • ACR Convergence 2025
    • Download Abstract Supplements
  • Keyword Index
  • Search
  • My Favorites
    • View and print all favorites
    • Clear all favorites

Abstract Number: 1605

Elevated Regulatory Mediators and Interferon Gamma Associated Responses, but Not Interferon Alpha, BLyS or IP-10, Accompany High-Titer Anti-Ro Autoantibodies in Asymptomatic Mothers of Children with Neonatal Lupus

Peter M. Izmirly1, Robert M. Clancy2, Melissa Munroe3, Sara Rasmussen2, Amit Saxena2,4, Jose U. Scher2, Aikaterini Thanou5, Stan Kamp6, Joan T. Merrill7, Jill P. Buyon2 and Judith James8, 1Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 2Department of Medicine, Division of Rheumatology, New York University School of Medicine, New York, NY, 3Arthritis and Clinical Immunology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 4Rheumatology, New York University School of Medicine, New York, NY, 5Arthritis and Clinical Immunology Reseach Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 6Clinical Pharmacology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK, 7Clinical Pharmacology, Oklahoma Medical Research Foundation, Oklahoma City, OK, 8Arthritis & Clinical Immunology Research Program, Oklahoma Medical Research Foundation, Oklahoma City, OK

Meeting: ACR/ARHP Annual Meeting 2014

Keywords: autoimmunity and cytokines, Lupus, Sjogren's syndrome

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print
Session Information

Title: Systemic Lupus Erythematosus - Human Etiology and Pathogenesis: Autoimmune Disease Transition, Disease Subsets and Prediction of Flares, Cytokines and Autoantibodies

Session Type: Abstract Submissions (ACR)

Background/Purpose: Mothers of children with neonatal lupus offer a unique opportunity to study the drivers and consequences of autoantibody production in the absence of ongoing maternal inflammation/damage or concurrent immunotherapeutics since many of these women are clinically asymptomatic with high titer anti-Ro antibodies identified solely by disease in the child.  This study was initiated to assess the contribution of soluble mediators in the  innate, adaptive and effector arms of the immune system to the production of anti-Ro responses independent of other autoantibodies or established systemic lupus erythematosus (SLE), Sjogren’s syndrome (SS) or rheumatoid arthritis (RA).    

Methods: Soluble mediators (N= 32) were examined including cytokines, chemokines, and soluble receptors using validated multiplex bead-based (xMAP) or enzyme-linked immunosorbent assays in serum from 44 anti-Ro positive women within 5 years of a pregnancy complicated by either heart block (N=36) or skin rash (N=8). Autoantibodies were measured by Bio-Rad Bioplex ANA2200 and recombinant and native Ro60/52 proteins by ELISA.  Antibodies to dsDNA, Sm, and RNP were all negative. Based on questionnaire, phone interview, and review of medical records, 18 mothers were completely asymptomatic, 8 had either photosensitivity or Raynauds, and 18 had a combination of mild complaints, including articular and cutaneous symptoms and did not fulfill SLE (ACR or SLICC), SS or RA criteria. Comparisons were made with sera obtained from 156 healthy controls and 94 SLE patients (30 = anti-Ro positive). 

Results:   Compared to healthy controls, asymptomatic/undifferentiated anti-Ro positive mothers had significant (p<0.0001) alterations in 21 of 32 tested mediators. These mothers had higher levels of IFN g and associated molecules (MIG, MIP-1a) (p<0.0001) than ANA negative healthy controls at levels that were comparable with SLE patients. However, levels of IFNa and associated molecules important in SLE (BLyS, IP-10) were much lower in anti-Ro positive mothers than SLE patients, and similar to healthy controls (p<0.0001). These anti-Ro positive mothers also had higher levels of Th17 (IL-17A, IL-21, IL-6), Th1 (IL-2, TNFa), Th2 (IL-4, IL-6), shed TNF receptors (TNFRI, TNFRII, sCD40L) and regulatory responses (IL-1RA) compared to healthy controls (p<0.0001). In addition, these anti-Ro positive mothers had dramatically higher levels of IL-1RA and TGFb compared to SLE patients including those with anti-Ro (p<0.0001). No significant differences in soluble mediator levels were noted between anti-Ro positive mothers who were completely asymptomatic and those with mild rheumatic symptoms.

Conclusion: High titer anti-Ro positive asymptomatic neonatal lupus mothers have dysregulated levels of soluble mediators across several inflammatory and immune pathways; however, BlyS and IP10, which appear temporally important in transition to clinical SLE, are not elevated.  This cohort provides a unique opportunity to dissect critical pathways resulting in autoimmunity absent overt disease, thus guiding the  development of targeted therapeutics for decreasing anti-Ro antibodies and risk of neonatal lupus, as well as providing insights into lupus pathogenesis.


Disclosure:

P. M. Izmirly,
None;

R. M. Clancy,
None;

M. Munroe,
None;

S. Rasmussen,
None;

A. Saxena,
None;

J. U. Scher,
None;

A. Thanou,
None;

S. Kamp,
None;

J. T. Merrill,
None;

J. P. Buyon,
None;

J. James,
None.

  • Tweet
  • Email a link to a friend (Opens in new window) Email
  • Print (Opens in new window) Print

« Back to ACR/ARHP Annual Meeting 2014

ACR Meeting Abstracts - https://acrabstracts.org/abstract/elevated-regulatory-mediators-and-interferon-gamma-associated-responses-but-not-interferon-alpha-blys-or-ip-10-accompany-high-titer-anti-ro-autoantibodies-in-asymptomatic-mothers-of-children-with-n/

Advanced Search

My Favorites

Save and print abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract (must have cookies enabled in browser). See saved favorites.

Abstract Policies

  • ACR Convergence Abstract Embargo Policies
  • ACR Convergence Abstract Permissions & Reprints
  • PRSYM Abstract Policies

ACR Convergence. Where Rheumatology Meets

ACR Convergence 2026

Join us November 6-11 in Orlando, Florida.
See Registration Information

  • Contact ACR
  • Privacy Policy
  • ACR Policies
  • Cookie Preferences

© Copyright 2026 American College of Rheumatology